-
1.发明公开IN VITRO MULTIPARAMETER-BESTIMMUNGSVERF AHREN ZUR DIAGNOSE UND FRÜHDIAGNOSE VON NEURODEGENERATIVEN ERKRANKUNGEN 有权体外多参数BESTIMMUNGSVERF年的诊断和痴呆病症的早期诊断
公开(公告)号：EP2030023A1
公开(公告)日：2009-03-04
申请号：EP07764672.7
申请日：2007-06-15
IPC分类号： G01N33/68
CPC分类号： G01N33/6896 , G01N2800/28 , G01N2800/2814 , G01N2800/2821 , Y10S436/811
摘要： In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.
-
2.发明授权
公开(公告)号：EP1517692B1
公开(公告)日：2008-07-23
申请号：EP03727273.9
申请日：2003-04-02
发明人： BERGMANN, Andreas
IPC分类号： A61K31/70
CPC分类号： A61K31/70
摘要： The invention relates to the use of Asialo-Gm1 (Agm1,) and/or GM gangliosides, and substances which simulate the carbohydrate part of said gangliosides in terms of binding to anti-AGm1 antibodies and/or anti-Gm1 antibodies, for producing an agent which blocks or binds to anti-AGm1 antibodies and/or anti-Gm1 antibodies which bind to natural killer cells (NKC), said agent being administered to patients at high risk of sepsis and to patients with sepsis, in whom such antibodies have been detected, for the prevention, inhibition and treatment of sepsis.
-
公开(公告)号：EP1770397A1
公开(公告)日：2007-04-04
申请号：EP06026319.1
申请日：1999-10-13
IPC分类号： G01N33/74 , C07K14/585 , A61K38/23 , A61K38/22
CPC分类号： G01N33/74 , C07K14/585 , G01N2333/585
摘要： Isoliertes Procalcitonin 3-116, Verfahren zur seiner Isolierung aus dem Blut von Sepsispatienten und die Verwendung von Procalcitonin 3-116 als Parameter in der allgemeinen Diagnostik.
摘要翻译： 用于早期识别败血症或严重感染，特别是败血症样全身感染的鉴别诊断的方法（I）是新的。 一种用于鉴别诊断早识别败血症或严重感染，特别是败血症样全身性感染的方法（I）是新的，包括确定，患者样品中：（a）至少一种肽激素原的量（II） ，除了降钙素原，和/或衍生的肽，（II）的存在和/或量被与败血症或类似感染，其严重性和/或治疗的结果的存在相关; 或（b）二肽基肽酶IV（III）的血清或血浆样品中的量，具有显著降低的水平指示败血症或类似感染。 还包括以下独立权利要求：（1）通过基因技术方法生产的降钙素原3-116（IV）; （二）生产（四）; 和（3）用于测量（IV）作为指示独立诊断参数的方法。 活性：抗炎; 抗菌; 免疫抑制。 行动机制：无给予。
-
4.发明公开DIAGNOSE VON SEPSIS DURCH SELEKTIVE BESTIMMUNG DER KONZENTRATION DER CU/ZN SUPEROXIDDISMUTASE (CU/ZN SOD) IN PATIENTENPROBEN 有权败血症的用Cu / Zn超氧化物歧化酶的患者样品浓度（铜/锌超氧化物歧化酶）的选择性测定诊断
公开(公告)号：EP1711831A1
公开(公告)日：2006-10-18
申请号：EP05701314.6
申请日：2005-02-02
IPC分类号： G01N33/68 , G01N33/569 , C12Q1/28
CPC分类号： C12Q1/28 , G01N33/56911 , G01N33/6893 , G01N2800/26
摘要： The invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD or SOD-1) in a serum sample or plasma sample of a patient of this type is selectively determined, and quantitatively or semiquantitatively measured concentrations, which exceed a predetermined threshold value, e.g. greater than approximately 310 ng/ml, are correlated with a high risk of mortality.
-
5.发明授权Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens 有权一种用于确定内皮素的形成用于医疗诊断的目的，以及抗体和试剂盒用于执行这样的方法的方法
公开(公告)号：EP1564558B1
公开(公告)日：2005-12-07
申请号：EP04003295.5
申请日：2004-02-13
IPC分类号： G01N33/74 , G01N33/68 , G01N33/574
CPC分类号： C07K16/00 , G01N33/57488 , G01N33/6893 , G01N33/74 , G01N2333/5754 , Y10S435/975
-
6.发明授权
公开(公告)号：EP1488209B1
公开(公告)日：2005-12-07
申请号：EP04700013.8
申请日：2004-01-29
发明人： BERGMANN, Andreas , STRUCK, Joachim
CPC分类号： G01N33/54306 , G01N33/574 , G01N33/6893 , G01N33/74 , G01N2800/26
摘要： The invention relates to a method for identifying adrenomedullin immunoreactivity in biological liquids for diagnostic purposes and, to be precise, particularly within the scope of sepsis diagnosis, cardiac diagnosis and cancer diagnosis. According to the invention, the midregional partial peptide (mid-proAM; SEQ ID NO:3) of the proadrenomedullin, which contains amino acids (45-92) of the entire preproadrenomedullin (pre-proAM; SEQ ID NO:1), is measured, in particular, with an immunoassay which works with at least one labeled antibody that specifically recognizes a sequence of the mid-proAM.
-
公开(公告)号：EP1499896A1
公开(公告)日：2005-01-26
申请号：EP03724960.4
申请日：2003-04-04
发明人： BERGMANN, Andreas
IPC分类号： G01N33/574 , G01N33/564
CPC分类号： G01N33/564 , G01N33/57488 , G01N2405/10
摘要： Disclosed is a method for the early detection of neoplasms in a patient and for assessing the danger represented by developing and/or spreading malignant neoplasms. The inventive method is characterized by the fact that the presence and quantity of antibodies (i) which bond to ganglioside structures and antigen structures simulating ganglioside structures, and (ii) the presence of which and/or the quantities of highly sensitive antibodies being significantly greater than in normal individuals correlating with the existence of a neoplasm and/or the patient's health being jeopardized by malignant neoplasms, is determined in a biological sample of the patient by using an assay that is highly sensitive to the antibodies that are to be determined.
-
8.发明公开
公开(公告)号：EP1499392A1
公开(公告)日：2005-01-26
申请号：EP03747405.3
申请日：2003-04-04
发明人： BERGMANN, Andreas
CPC分类号： A61K39/0011
摘要： Disclosed are uses of gangliosides GM1 and/or asialo-GM1 and substances simulating the carbohydrate portion of said gangliosides with regard to bonding to anti-GM1 antibodies and/or anti-AGM1 antibodies for producing agents which bind or block anti-GM1 antibodies and/or anti-AGM1 antibodies which bond to natural killer cells (NKC) or for blocking antigen-presenting cells and producing a T-cell anergy, and for producing an affinity material for the extracorporeal removal of anti-GM1 antibodies and/or anti-AGM1 antibodies in order to prevent, inhibit, and treat malignant cancers.
-
公开(公告)号：EP1318404B1
公开(公告)日：2004-07-28
申请号：EP01128850.3
申请日：2001-12-04
IPC分类号： G01N33/68 , G01N33/569
CPC分类号： G01N33/56911 , G01N33/6893 , G01N2800/26
-
公开(公告)号：EP1408334A1
公开(公告)日：2004-04-14
申请号：EP03028136.4
申请日：1999-10-13
IPC分类号： G01N33/74 , C07K14/585 , A61K38/23 , A61K38/22
CPC分类号： G01N33/74 , C07K14/585 , G01N2333/585
摘要： Rekombinantes Procalcitonin 3-116 und seine Verwendungen im Rahmen von Diagnose und Therapie.
摘要翻译： 用于早期识别败血症或严重感染，特别是败血症样全身感染的鉴别诊断的方法（I）是新的。 用于早期识别败血症或严重感染，特别是败血症样全身感染的鉴别诊断的方法（I）是新的，包括在患者样品中测定：（a）至少一种肽激素原（II） （II）的存在和/或量与败血症或类似感染的存在，其严重性和/或治疗结果相关联; 或（b）血清或血浆样品中二肽基肽酶IV（III）的量，显着降低的水平指示败血症或类似感染。 还包括以下独立权利要求：（1）通过基因技术方法生产的降钙素原3-116（IV）; （二）生产（四）; 和（3）用于测量（IV）作为指示独立诊断参数的方法。
-
-
-
-
-
-
-
-
-
搜索结果
79 条记录 (耗时 0.022 秒)
